Christophe Moreno
Université libre de Bruxelles
281 Papers
1.9K Citations
Christophe Moreno is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 53, co-authored 259 publications. Previous affiliations of Christophe Moreno include Free University of Brussels & University of Toronto.
Chat about Author
Papers
Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey's discriminant function <32.
Delphine Degré,Rudolf E Stauber,Gaël Englebert,Francesca Sarocchi,Laurine Verset,Florian Rainer,Walter Spindelboeck,Hassane Njimi,Eric Trepo,Thierry Gustot,Carolin Lackner,Pierre Deltenre,Christophe Moreno +12 more
TL;DR: Mortality of patients with alcoholic hepatitis and an mDF <32 presenting with an acute decompensation is around 50% at 5 years, and new treatment strategies, including measures to ensure abstinence, are required.
Liver transplant for alcoholic hepatitis: a current clinical overview.
TL;DR: A strict selection process based on a good psychosocial profile, including social stability, no previous treatments for alcohol dependence, no current drug use, and no co-existing severe mental disorder seems to be the best way to manage severe alcoholic hepatitis issues.
Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study
Hélène Vandenbulcke,Christophe Moreno,Isabelle Colle,Jean-François Knebel,Sven Francque,Thomas Sersté,Christophe George,Chantal de Galocsy,Wim Laleman,Jean Delwaide,Hans Orlent,L Lasser,Eric Trepo,Hans Van Vlierberghe,Peter Michielsen,Marc Van Gossum,Marie de Vos,Astrid Marot,Christopher Doerig,Jean Henrion,Pierre Deltenre,Pierre Deltenre +21 more
TL;DR: Light-to-moderate alcohol intake is associated with the risk of hepatocellular carcinoma in patients with compensated HCV-related cirrhosis in multivariate analysis and should be strongly advised against any alcohol intake.
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Stefan Zeuzem,Peter Buggisch,Kosh Agarwal,Patrick Marcellin,Daniel Sereni,Hartwig Klinker,Christophe Moreno,Jean-Pierre Zarski,Yves Horsmans,Hongmei Mo,Sarah Arterburn,Steven J. Knox,David W. Oldach,John G. McHutchison,Michael P. Manns,Graham R. Foster +15 more
TL;DR: In genotype 1 HCV, adding RBV or RBV with Peg‐IFN provides additive antiviral activity to combination therapy with tegobuvir and GS‐9256, and the primary efficacy endpoint was rapid virologic response (RVR).